Cultivating Brands Embracing Technological Advancement 培育品牌 發展先進科技 JACOBSON PHARMA CORPORATION LIMITED 雅 各 臣 科 研 製 藥 有 限 公 司 2017 INTERIM REPORT 中 期 報 告 雅各臣科研製藥有限公司 根據開曼群島法例註冊成立的有限公司 股份代號 : 2633 二零一七年中期報告 JACOBSON PHARMA CORPORATION LIMITED Incorporated under the laws of the Cayman Islands with limited liability Stock Code : 2633 Interim Report 2017

2 3 4 6 7 8 18 26 27 28 29 30 31 44

Cricket Square Hutchins Drive PO Box 2681 Grand Cayman KY1-1111 Cayman Islands 388 1 1 23 2313-18 Conyers Trust Company (Cayman) Limited Cricket Square Hutchins Drive PO Box 2681 Grand Cayman KY1-1111 Cayman Islands 183 22 2633 www.jacobsonpharma.com

003 542,225 506,617 +7.0% 121,183 68,832 +76.1% 79,624 743,032 575,449 +29.1% 278,904 244,612 +14.0% 37.5% 42.5% 80,329 57,052 +40.8% 10.8% 9.9% EBITDA (1) 166,243 129,411 +28.5% EBITDA (2) 22.4% 22.5% (3) 9.2% 9.2% 3,066,785 2,970,067 +3.3% 1,224,801 1,197,749 +2.3% 1,841,984 1,772,318 +3.9% (1) EBITDA EBITDA (2) EBITDA EBITDA100% (3) 100%

004 (losartan)(mesalazine) (losartan) 87.5% 76.2% (bisacodyl suppository)29.6% Salesforce.com 20 1. (lamivudine) (atorvastatin) (rosuvastatin) (ezetimbe) (trimetazidine modified release) 2. 10 (trastuzumab) (rituximab)(infliximab) 10 3. 4. 5.

005 Dignari Hillhouse 5 2.50

006

007 30% 70% 20% 1,000

008 542.27.0% 184.2170.7 7.9%358.0 335.9 6.6% 19.3% 17.8% (antiulcerants)(antihypertensives) 21.6% 23.7% (rosuvastatin)(irbesartan)(telmisartan) (quetiapine) (entecavir)(lamivudine)(zidovudine) (losartan) 87.5% (zolpidem) 2,000 Salesforce.com 17.3% 37.0% 4.9% 1,341135137.3 PIC/S GMP 19.1%

009 18.1% 13.4% PIC/S 2.4100% 121.268.8 76.2% 8% 7% 7.4 45.2 3.4 18 8 22

010 (NAMI) NAMI 45 NanoAZD TM (Alzheimer s Association International Conference) 1,910212.5 175.2

011 121.2, 16% 79.6, 11% 68.8, 12% 743.0 575.4 542.2, 73% 506.6, 88% 167.629.1% 35.652.4 79.6 73% 16% 11% 13.522.1 45.2

012 18.9, 3% 19.6, 3% 16.7, 2% 10.6, 1% 11.1, 2% 8.9, 2% 743.0 575.4 696.8, 94% 535.8, 93% 94% 161.0 122.0, 26% 92.6, 28% 464.1 213.0, 46% 330.8 135.4, 41% 129.1, 28% 102.8, 31%

013 46% 26.325.6% 140 120 100 80 100.9 22.6 60 112.7 112.7 40 78.3 78.3 20 0 100.9 11.811.7% 112.7 34.3 11.410.7

014 100 80 79.7 22.6 60 40 57.1 80.3 57.1 80.3 20 0 0.60.8% 80.3 42.8 33.7 59.0%98.9% 937.5949.1

015 695.5 98.4 139,108 138,933 104,331 8,000 69,554 69,000 113,197 101,300 12,000 12,000 94,331 10,816 10,000 1,533 83,465 31,709 69,554 61,437 695,540 434,728 409.3466.9 56.0 100%32.6% 33.8%

016 Dragons 615 Limited HH InRe JP, Ltd. 2.50500 3.5 Dragons 615 Limited DCP China Credit Fund I, L.P. DCP China Credit Fund I, L.P. HH InRe JP, Ltd. Hillhouse InRe Fund, L.P. 1,000,000 2.13 0.01 1,000,000

017

018 A.2.1

019 2410 0.916.3 0.8 9 18322 13.18 13.21 500 3.5% 2.50 200,000,000 500

020 13.51B (1) (a) 8,539,0004,093,798 1,818,0001,200,000 (b) 200,000208,000 (c) 200,000208,000 (d) 200,000208,000 (e) 200,000208,000 (f) (g)

021 XV XV7 8 352 347 (I) (1)(2) 1,289,186,000 71.01% 15,350,000 0.85% 1,220,000 0.07% 364,000 0.02% (1) The Jacobson Pharma (PTC) LimitedThe Jacobson Pharma (PTC) Limited QueenshillQueenshillThe Jacobson Pharma (PTC) Limited 19,702,000Queenshill (2) UBS Trustees (B.V.I.) Limited The Kingshill Trust UBS Nominees LimitedKingshill Development Group Inc.Trust Co Trust CoKingshillKingshill850,684,000The Kingshill Trust The Queenshill Trust The Kingshill Trust The Queenshill TrustKingshill 850,684,000 (II) 13,500,000 0.74% 4,500,000 0.25% (II) (I)

022 XV XV7 8 352 347 XV2 3 336 (I) Queenshill (1) 281,452,000 15.50% Kingshill (2) 1,007,734,000 55.50% Longjin (2) 1,007,734,000 55.50% Trust Co (3) 1,007,734,000 55.50% UBS Trustees (B.V.I.) Limited (3) 1,007,734,000 55.50% (2) 1,007,734,000 55.50% (1)(3) 1,289,186,000 71.01% (1) The Jacobson Pharma (PTC) LimitedThe Jacobson Pharma (PTC) Limited QueenshillQueenshillThe Jacobson Pharma (PTC) Limited 19,702,000Queenshill (2) Kingshill Longjin Kingshill The Kingshill Trust Trust CoThe Kingshill Trust Longjin 75% (3) UBS Trustees (B.V.I.) Limited The Kingshill Trust UBS Nominees LimitedTrust CoTrust Co KingshillKingshill850,684,000The Kingshill Trust The Queenshill Trust UBS Trustees (B.V.I.) Limited Trust Co Kingshill Kingshill 850,684,000

023 (II) Dragons 615 LimitedDragons 615 Limited 2.50 280 DCP China Credit Fund I, L.P. 112,000,000 6.17% Dignari Capital Partners GP Limited 112,000,000 6.17% 112,000,000 6.17% Dragons 615 Limited DCP China Credit Fund I, L.P.Dignari Capital Partners GP Limited 336 139,000,0007.66% 301 12 1%

024 (i)(ii) (iii) 36,000,000 13,500,000 13,500,000 4,500,000 4,500,000 2.06 2.06 18,000,000 18,000,000 18,000,000 18,000,000 2.06 36,000,000 36,000,000

025 6,000,000 6,000,000 6,000,000 14(B)

026 27 43 34 34 2410 34 10 8

027 4 743,032 575,449 (464,128) (330,837) 278,904 244,612 5 3,702 4,186 (83,962) (72,601) (85,940) (97,869) 112,704 78,328 6(A) (13,874) (1,905) 6 98,830 76,423 7 (15,762) (17,133) 83,068 59,290 1,496 (973) 1,496 (973) 84,564 58,317 80,329 57,052 2,739 2,238 83,068 59,290 81,825 56,079 2,739 2,238 84,564 58,317 8 4.42 4.27 8 4.42 4.27 9 31 43

028 10 998,092 1,007,672 48,428 48,839 10 56,000 1,086,464 1,056,801 20,595 20,420 4,924 2,423 2,214,503 2,136,155 288,563 261,313 11 228,878 201,470 8,501 11,444 12 326,340 359,685 852,282 833,912 13 108,959 108,141 949,144 937,486 149 149 26,444 12,713 1,084,696 1,058,489 232,414 224,577 1,982,089 1,911,578 298 373 139,807 138,887 140,105 139,260 1,841,984 1,772,318 14 18,156 18,156 1,791,153 1,731,247 1,809,309 1,749,403 32,675 22,915 1,841,984 1,772,318 31 43

029 13,125 6,445 126,645 5,787 754,880 906,882 49,263 956,145 57,052 57,052 2,238 59,290 (973) (973) (973) (973) 57,052 56,079 2,238 58,317 14 4,375 615,982 620,357 620,357 (520) (520) 17,500 622,427 126,645 4,814 811,932 1,583,318 50,981 1,634,299 18,156 717,058 90,564 3,942 919,683 1,749,403 22,915 1,772,318 80,329 80,329 2,739 83,068 1,496 1,496 1,496 1,496 80,329 81,825 2,739 84,564 15 7,021 7,021 9(B) (25,419) (25,419) (25,419) 14(B) 3,500 3,500 3,500 18,156 717,058 94,064 5,438 974,593 1,809,309 32,675 1,841,984 31 43

030 127,109 99,818 (494) 302 126,615 100,120 (94,739) (50,062) 3,522 1,277 2,628 15 (38,992) 51 8 (132,403) (43,904) 403,540 464,877 (391,597) (260,658) (36,202) 14 656,250 (30,209) (25,419) (224,800) (520) (14,234) (8,411) (27,710) 560,327 (33,498) 616,543 12 359,685 82,925 153 (96) 12 326,340 699,372 31 43

031 1 2 34 3 34 527,897,000517,258,000 2410 26 3

032 3 4 (A) (B) EBITDA EBITDA

033 4 (B) (i) 542,225 506,617 121,183 68,832 79,624 743,032 575,449 1,639 2,344 3,983 543,864 506,617 123,527 68,832 79,624 747,015 575,449 EBITDA 125,780 120,780 39,794 8,631 2,189 167,763 129,411 (ii) 747,015 575,449 (3,983) 743,032 575,449 167,763 129,411 (1,520) 166,243 129,411 31 8 1,634 2,393 2,599 237 (22,610) (56,406) (32,508) (13,874) (1,905) 98,830 76,423

034 4 (B) (iii) 696,832 535,750 18,927 19,619 16,654 11,178 3,384 3,624 7,235 5,278 743,032 575,449 2,174,985 2,103,052 30,289 30,532 140 148 2,205,413 2,133,732 (iv) 10% 184,158,000 170,715,000

035 5 336 235 31 8 1,634 99 (90) (110) (51) 2,393 2,599 237 510 57 3,702 4,186 6 (A) 13,855 8,205 19 23 13,874 8,228 (6,323) 13,874 1,905 (B) 818 583 12,826 7,553 10 42,762 24,372 8,011 5,699 4,234 251 3,500 22,610

036 7 17,265 14,715 (1,503) 2,418 15,762 17,133 16.5% 16.5% 8 80,329,00057,052,000 1,815,625,0001,336,407,000 1,815,625 1,312,500 14 23,907 1,815,625 1,336,407

037 8 80,329,00057,052,000 1,815,625,0001,336,672,000 1,815,625 1,336,407 265 1,815,625 1,336,672 500,000,000 3.5 200,000,000 9 (A) 0.9 0.8 16,341 14,525 (B) 1.4 25,419

038 10 (A) 1,277,202 1,057,090 33,670 259,974 15 22 (42,206) (34,608) 4,169 (5,254) 1,272,857 1,277,202 269,530 241,767 42,762 62,264 (40,819) (30,570) 3,292 (3,931) 274,765 269,530 998,092 1,007,672 (B) 53,401,000 2,599,000

039 11 115,982 102,616 66,447 51,698 594 183,023 154,314 4,237 2,762 41,618 44,394 228,878 201,470 12 326,340 359,685 13 23,144 21,462 11,730 19,394 74 38 34,948 40,894 44,642 38,793 1,229 1,973 25,026 23,326 3,114 3,155 108,959 108,141

040 14 (A) 1,312,500 13,125 437,500 4,375 65,625 656 1,815,625 18,156 1.50 437,500,000 0.01620,357,00035,893,000 4,375,000 615,982,000 1.50 65,625,000 0.0195,287,0003,150,000 656,000 94,631,000 (B) 6,000,000 1.61.6 1 36,000,000 2.06

041 15 56,000,000 70% 79,624,000550,000 4,466,000 388,000 22 16,070 1,783 11,408 (5,877) 23,406 (7,021) (52,071) 35,686 56,000 (3,929) 52,071 56,000 (11,408) (5,600) 38,992

042 15 8,000,000 5,000,000 3,929,000 4,166,000 712,000 16 13 4,166,000 15 10% 285,000

043 17 50,400 6,098 10,166 6,098 60,566 18 (A) 4,969 7,539 169 161 1,763 6,901 7,700 (B) 77,225,000 19 500,000,000 3.5 1,000,000 2.13 0.01 1,000,000

044 EBITDA EBITDA EBITDA100% Kingshil Kingshill Development Group Inc Longjin Kingshill Longjin Dignari Dignari Capital Partners GP Limited DCP China Credit Fund I, L.P. Dragons 615 Limited GMP Hillhouse Hillhouse InRe Fund, L.P. HH InRe JP, Ltd.

045 Kingshill Kingshill Development Limited NAMI 100% PIC/S GMP PIC/S GMP PIC/S PIC/S GMP Queenshill Queenshill Development Limited 571 0.01 D.2.

046 D.1. The Kingshill Trust The Kingshill Trust The Queenshill Trust The Queenshill Trust